Higher doses of semaglutide (2.4 mg weekly, Wegovy) have been specifically licensed for weight management in individuals with obesity, reflecting the medication's potent effects on appetite regulation
You can read the abstract of this article at The high rate of failure in drug development is a significant problem, with only a small fraction of compounds successfully making it through the entire process and gaining regulatory approval
Furthermore, the risk of supplement contamination is a huge problem
However, although the mean baseline A1C over time has decreased for people with T2D, at the end of the study period, the A1C value was still over 6.5% (the percent at which diabetes is diagnosed) (Centers for Disease Control and Prevention, 2022)
Infatti il farmaco pu causare nausea, vomito, diarrea, disidratazione, ma anche ipoglicemia, soprattutto se associato ad altri farmaci per il diabete
PRRT using [111In-DTPA]-octreotide (where DTPA is diethylenetriamine pentaacetic acid) is feasible because, besides gamma radiation, 111In emits both therapeutic Auger and internal conversion electrons having tissue penetration ability [39, 40]
